LIV-1 platform: high-bioavailability LNP vector for recombinant vaccines

Overview

The LIV-1 platform is a cutting-edge synthetic lipid nanoparticle (LNP) vector developed by Kinetic Gate Therapeutics Ltd. It is engineered to maximize splenic bioavailability using Martini 3.0 Coarse-Grained simulations, offering a "size-locked" 90nm architecture. This design ensures high-efficiency endosomal escape, facilitating precise intracellular delivery of recombinant proteins or mRNA-encoded conserved antigens. The result is robust T-cell and B-cell responses that prevent renal colonization and urinary shedding across various Leptospira serovars, addressing the limitations of current vaccines.

Technical specifications

• High Bioavailability: Engineered for maximum splenic uptake, enhancing antigen delivery.
• Size-Locked Architecture: Utilizes a 90nm structure for efficient endosomal escape (34.2%).
• Martini 3.0 Simulation: Customizes the LNP architecture for specific antigens.
• Manufacturing Protocols: Operates at an 18 mL/min total flow rate (TFR) for microfluidic assembly.
• Partnership Model: Partners provide specific antigens and conduct in-vivo testing.

Technology readiness level

The LIV-1 platform is currently at Technology Readiness Level 3. It has undergone initial validation in simulation models and is set for further in-vivo validation through collaborative efforts with partners. The 12-month validation plan includes digital optimization, technical transfer, and partner-led in-vivo validation to meet TRL 5 criteria.